<?xml version="1.0" encoding="UTF-8"?>
<p>Sphingolipids are important lipids that regulate membrane properties such as viscosity and tension, which might also make them suitable as novel targets for therapeutic intervention [
 <xref rid="B65-ijms-21-03544" ref-type="bibr">65</xref>,
 <xref rid="B66-ijms-21-03544" ref-type="bibr">66</xref>,
 <xref rid="B67-ijms-21-03544" ref-type="bibr">67</xref>]. Sphingolipid biosynthesis is modulated in so many diseases, and mutations impacting their metabolism have been shown to cause disease [
 <xref rid="B65-ijms-21-03544" ref-type="bibr">65</xref>,
 <xref rid="B66-ijms-21-03544" ref-type="bibr">66</xref>,
 <xref rid="B67-ijms-21-03544" ref-type="bibr">67</xref>,
 <xref rid="B68-ijms-21-03544" ref-type="bibr">68</xref>,
 <xref rid="B69-ijms-21-03544" ref-type="bibr">69</xref>,
 <xref rid="B70-ijms-21-03544" ref-type="bibr">70</xref>]. The sphingolipid biosynthesis pathway starts with the formation of 3-ketosphinganine from serine and palmitoyl-CoA by serine palmitoyltransferase (SPT). SPT is composed of two major subunits and several small subunits that are most likely involved in its regulation and specificity [
 <xref rid="B71-ijms-21-03544" ref-type="bibr">71</xref>,
 <xref rid="B72-ijms-21-03544" ref-type="bibr">72</xref>]. As sphingolipids, especially ceramides and glucosylceramides, accumulate in a wide variety of diseases, sphingolipid biosynthesis is widely viewed as a therapeutic target for many different indications [
 <xref rid="B65-ijms-21-03544" ref-type="bibr">65</xref>,
 <xref rid="B66-ijms-21-03544" ref-type="bibr">66</xref>,
 <xref rid="B67-ijms-21-03544" ref-type="bibr">67</xref>].
</p>
